InnoCan Pharma Corporation (INNO.CN)
| Previous Close | 0.3100 |
| Open | 0.3000 |
| Bid | 0.2900 x N/A |
| Ask | 0.3100 x N/A |
| Day's Range | 0.3000 - 0.3000 |
| 52 Week Range | 0.1950 - 0.8000 |
| Volume | |
| Avg. Volume | 43,182 |
| Market Cap | 74.886M |
| Beta (5Y Monthly) | 3.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0320 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting
- Newsfile
Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and ar
- Newsfile
Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Giv
